Accelerate Biosimilar Development with High-Throughput Kinetic Screening

As the biosimilar market continues to expand, the need for efficient, cost-effective, and reliable development processes becomes paramount.

Our cutting-edge technology offers unparalleled insights into biomolecular interactions, streamlining the path to market for biosimilars. This application note highlights how label-free biomolecular interaction analysis in real-time can be utilized for high-throughput kinetic screening transform your biosimilar development process.

Key Benefits:

• High throughput screening of binding kinetics for for faster decisions.
• Ensure biosimilarity with regulatory-compliant binding data.
• Streamline downstream processing with simplified analytis.
• Fluidic-free and label-free technology.
• Direct analysis of unpurified samples identifying optimal clones early.
• Unlock several critical quality attributes (CQAs) for process optimization in one run.

Why Choose Octet® BLI?

• With the ability to assess multiple samples simultaneously, maximize data output, facilitating comprehensive studies and accelerating the path to discovery.
• Achieve precise kinetic and equilibrium binding constant measurements, ensuring compliance with stringent regulatory standards and enhancing the credibility of your research.
• Eliminate the need for sample purification and analyze directly, saving valuable time and resources while maintaining the integrity of your research.

As the patents for major drugs expire, the biosimilar market is poised for unprecedented growth. Octet® BLI systems empower researchers and scientists to navigate this complex landscape with confidence, ensuring high similarity to reference medicinal products and accelerating the journey from concept to market.